- Home
- NODK vs INAB Comparison
NODK vs INAB Comparison
Compare NODK & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- INAB
- Stock Information
- Founded
- NODK 1946
- INAB 2016
- Country
- NODK United States
- INAB United States
- Employees
- NODK N/A
- INAB N/A
- Industry
- NODK Property-Casualty Insurers
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- NODK Finance
- INAB Health Care
- Exchange
- NODK Nasdaq
- INAB Nasdaq
- Market Cap
- NODK 327.3M
- INAB 24.0M
- IPO Year
- NODK 2017
- INAB 2021
- Fundamental
- Price
- NODK $15.31
- INAB $0.25
- Analyst Decision
- NODK
- INAB Strong Buy
- Analyst Count
- NODK 0
- INAB 3
- Target Price
- NODK N/A
- INAB $7.75
- AVG Volume (30 Days)
- NODK 26.8K
- INAB 748.9K
- Earning Date
- NODK 11-07-2024
- INAB 11-12-2024
- Dividend Yield
- NODK N/A
- INAB N/A
- EPS Growth
- NODK N/A
- INAB N/A
- EPS
- NODK N/A
- INAB N/A
- Revenue
- NODK $391,655,000.00
- INAB N/A
- Revenue This Year
- NODK N/A
- INAB N/A
- Revenue Next Year
- NODK N/A
- INAB N/A
- P/E Ratio
- NODK N/A
- INAB N/A
- Revenue Growth
- NODK 22.91
- INAB N/A
- 52 Week Low
- NODK $12.71
- INAB $0.22
- 52 Week High
- NODK $17.24
- INAB $1.93
- Technical
- Relative Strength Index (RSI)
- NODK 36.09
- INAB 39.26
- Support Level
- NODK $15.59
- INAB $0.28
- Resistance Level
- NODK $16.90
- INAB $0.32
- Average True Range (ATR)
- NODK 0.43
- INAB 0.03
- MACD
- NODK -0.17
- INAB -0.01
- Stochastic Oscillator
- NODK 3.02
- INAB 13.73
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.